The person depicted is a model used for illustrative purposes only.
Watch the MENVEO Clinical Study Design Video
MENVEO is the only MenACWY vaccine approved for use in infants as young as 2 months of age1
Most infants and toddlers who completed the 4-dose series had a protective immune response with MENVEO1
- The primary endpoint for MENVEO (adequacy of immune response) was met following the full 4-dose series, given at 2, 4, 6, and 12 months of age*
MENVEO demonstrated higher geometric mean titers (GMTs) post-dose 4 in infants and toddlers1
GMTs are a measure of the level of immune response to a vaccine in a specific study group. Infants and toddlers vaccinated with MENVEO were found to have circulating bactericidal antibodies to MenACWY following the full 4-dose series.
GMT=geometric mean titers; hSBA=serum bactericidal assay with exogenous human complement source.
*Prespecified criteria for adequacy of immune response were met (LL of the 95% CI >80% for serogroup A and >85% for serogroups C, W, and Y).
†hSBA GMTs at 1-month post-dose 3 and 1-month post-dose 4 of MENVEO with routine infant/toddler vaccines.
Randomized, controlled, multicenter study of infants initiating vaccination at 2 months of age with either MENVEO concomitantly with routine infant vaccines (diphtheria toxoid, tetanus toxoid, and acellular pertussis [DTaP], inactivated poliovirus [IPV] types 1, 2, and 3, hepatitis B, Haemophilus influenzae type b [Hib], pentavalent rotavirus, and 7-valent pneumococcal conjugate [PCV7]) or routine infant vaccines alone. Toddlers received the fourth dose of MENVEO concomitantly with PCV7, measles, mumps, rubella, and varicella (MMRV), and inactivated hepatitis A vaccines.1
- Prescribing Information for MENVEO.
- Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46(2):S9-S15.
- Meningococcal vaccines for preteens, teens. Centers for Disease Control and Prevention website. http://www.cdc.gov/features/meningococcal/. Updated April 18, 2016. Accessed October 6, 2017.
- Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:231-245. http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed October 6, 2017.
- Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479.
- Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604.
- MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed October 6, 2017.
- Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
- Centers for Disease Control and Prevention website. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis, 2005-2014. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed October 6, 2017.
- Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics. 2009;124(6):1633-1641.